Read the latest news.

NEWS

Aurion Biotech to Present Clinical Data at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 2, 2024 – Seattle, Cambridge and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced several presentations during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held April 5-8, 2024 in Boston, Massachusetts. At Eyecelerator and ASCRS 2024, data will be presented...
Read More

Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial

Allogeneic Cell Therapy for the Treatment ofCorneal Edema Secondary to Corneal Endothelial DysfunctionSeattle, Cambridge, Tokyo–(BUSINESS WIRE)— 28 March 2024—Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001,...
Read More

Greg Kunst, CEO of Aurion Biotech, Receives Healthcare Leadership Award from Puget Sound Business Journal

 SEATTLE, WA; CAMBRIDGE, MA and TOKYO, Japan – December 7, 2023 – Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that CEO Greg Kunst has won one of the Healthcare Leadership awards from the Puget Sound Business Journal (PSBJ). Each year, PSBJ celebrates outstanding leaders in health care...
Read More

Aurion Biotech Named “Regenerative Therapeutics Company Of The Year” By BioTech Breakthrough

Annual Awards Program Recognizes Innovation in Global Life Sciences and BiotechnologySEATTLE, CAMBRIDGE and TOKYO – November 8, 2023 – Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced it has been selected as “Regenerative Therapeutics Company of the Year” in the third annual BioTech Breakthrough Awards program...
Read More

The Importance of Teamwork

by Greg Kunst, CEOIt’s said that biotech is a “team sport.” Certainly, coordination, collaboration and consistently high performance are just some of the teamwork qualities that the Aurion Biotech team displayed in the months leading up to this week’s massively significant milestone, where we had the privilege of treating our first subjects in our ABA-1...
Read More

Aurion Biotech Announces First Subject Dosed in U.S. Phase 1 / 2 Clinical Trial

Allogeneic Cell Therapy for the Treatment of Corneal Edema Secondary to Corneal Endothelial DysfunctionSeattle, Cambridge, Tokyo–(BUSINESS WIRE)— 24 October 2023—Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first subject in its Phase 1 / 2 U.S. clinical trial (ABA-1, CLARA) of...
Read More

Aurion Biotech Wins Clinical Advance of the Year Award at Biotech Week Boston

Recognition for its innovative cell therapy for corneal endothelial diseasesSeptember 19, 2023 – Seattle, Cambridge and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced it has received the Clinical Advance of the Year award from Biotech Week Boston.“Aurion Biotech is advancing a game-changing cell...
Read More

Aurion Biotech to Present Clinical Trial Results at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Efficacy data from Escalón study shows improvements in central corneal thickness and best corrected visual acuity May 2, 2023 – Seattle, Cambridge and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced several presentations during the 2023 American Society of Cataract and Refractive Surgery (ASCRS)...
Read More

March Milestone

By Greg Kunst, CEO  A lot of things seem to happen in March – Caesar’s assassination, Shakespeare’s Ides (a fortune-teller’s warning of the aforementioned assassination), the Spring Equinox, and (of course) March Madness.But Aurion’s most recent March Milestone augurs only good things – especially for the millions of patients around the world who suffer from...
Read More

Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

First approval in the world forallogeneic cell therapy to treat corneal endothelial disease March 23, 2023 – Seattle, Cambridge MA and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMD A),...
Read More